GreenLight Clinical and Cure Therapeutics have conducted a signing ceremony in Sydney with the two companies looking to collaborate on the evaluation of potential cancer therapy.
The potential treatment is for patients with late-stage Myeloma.
GreenLight CEO Dr Grace Pei said, “We are excited for the opportunity to partner with Cure Therapeutics in pursuit of a treatment for patients with this potentially fatal condition. This Letter of Intent represents the first step in what we hope will be a long and successful working relationship between our respective companies for our patients.”
Cure Therapeutics CEO David Kim added, “We are very happy to team up with GreenLight to speed up the clinical availability of our unique NK cell therapy for MM patients who do not have any therapeutic options. In addition to collaboration for the first clinical study of our NK cell therapy, we will expand our partnership with GreenLight to accelerate the translation of our innovative therapeutic technologies into curable and affordable solutions for patients with life-threatening conditions.”
